Slides
Page 1
Myomo Investor & Analyst Day June 18, 2025 1
Page 2
Myomo, Inc. A nalyst D ay - June 18th 2025 • Direct Provider Business • Lead Generation • Field Operations • Reimbursement • Post-delivery Support • Manufacturing Tour and Overview • International Business • O&P Channel • Product Development • Finance • Wrap-Up and Q&A Agenda 2
Page 3
Myomo, Inc. A nalyst D ay - June 18th 2025 Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, the Company’s financial position and projections of future operating results, and the Company's future business expectations, which are based upon the current estimates, assumptions and expectations of the Company’s management and its knowledge of the relevant market. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. Forward- looking statements, which are included in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are only predictions and may differ materially from actual results due to a variety risks, uncertainties and other factors. These risks and uncertainties include, among others, risks related to the Company’s liquidity and financial position, the trading of its common stock, its new products, services, and technologies, government regulation and taxation, and fraud. More information about factors that potentially could affect Myomo's business and financial results are included in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. 3
Page 4
Opening Remarks Paul R. Gudonis CEO 4
Page 5
Myomo, Inc. Analyst Day - June 18th 2025 Paul R. Gudonis Chairman & CEO • 40+ years experience in building new technology companies at scale • Cell Phone Service • Enterprise Software • Internet Services • Global Robotics Competition • Joined Myomo 15 years ago: 4-person spinout from MIT • Created new product category and market leadership • MBA, Harvard Business School; BSEE, Northwestern University • Advisor to NU McCormick School of Engineering, Biomedical Engineering Council, NUvention Medical Device Course, Design for America 5
Page 6
Myomo, Inc. A nalyst D ay - June 18th 2025 • Provide a “Deeper Dive” into Myomo’s operations • Meet members of Myomo’s Senior Leadership team • Tour our new HQ and Production facilities • Test your EMG Signal with a MyoPro demo unit • Provide details regarding our long-term business plan • We won't be updating Q2 or 2025 guidance in this meeting • Listen to our guests Purpose of Today’s Investor / Analyst Day 6
Page 7
Myomo, Inc. A nalyst D ay - June 18th 2025 Myomo’s Strategic Position Created new product Category with MyoPro myoelectric orthosis First-mover advantage in meeting a large and growing unmet need 7 CMS reimbursement opened access to Medicare-age population Established direct provider business with new O&P channel Attractive margin profile with opportunity for scale economics
Page 8
Myomo, Inc. A nalyst D ay - June 18th 2025 Go-To-Market Model and Channels Myomo Direct Billing 79% of 1Q25 revenue VA 3% of 1Q25 revenue International 13% of 1Q25 revenue In-Country O&P Clinics US / O&P Clinics 5% of 1Q25 revenue 8
Page 9
Myomo, Inc. A nalyst D ay - June 18th 2025 Next Milestone - Growing Revenue to Address a Large Unmet Need 0 20 40 60 80 100 120 2024 2028 $32.4M $100M 9
Page 10
Myomo, Inc. A nalyst D ay - June 18th 2025 Myomo Leadership Team Board of Directors CEO Paul Gudonis Commercial Operations Micah Mitchell Marketing: Joseph Chicoskie Field Operations: Peter Young Clinical Services: Kathy Sawyers Medical Affairs Dr. Harry Kovelman Engineering & Product Strategy Malcolm Bock Manufacturing Operations Colin Anderson International John Frijters Finance Dave Henry 10
Page 11
Direct Billing Channel Micah Mitchell Chief Commercial Officer 11
Page 12
Myomo, Inc. Analyst Day - June 18th 2025 • Joined Myomo in 2018. • Oversees commercial operations with focus on expanding Myomo’s marketing, clinical sales and operations, clinical training, and distribution activities • 20+ years of experience providing high-end medical equipment to help disabled people to improve their quality of life • BS in Economics from Baylor University and an MBA from the McCombs School of Business at The University of Texas at Austin Micah Mitchell Chief Commercial Officer 12
Page 13
Myomo, Inc. Analyst Day - June 18th 2025 Direct Provider Process - Overview Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes 13
Page 14
Myomo, Inc. Analyst Day - June 18th 2025 Direct Provider Process - Overview Education via: • TV Ads • Social Media • Family/Friends • Physicians • Therapists • CPO’s Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes 14
Page 15
Myomo, Inc. Analyst Day - June 18th 2025 Patients’ first conversation(s) and/or telehealth screening and/or clinical evaluation to determine initial candidacy for a MyoPro. Successful Telehealth Screening = Pipeline Add Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes Direct Provider Process - Overview 15
Page 16
Myomo, Inc. Analyst Day - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes Patient completes “face-to-face” with their Physician who orders the MyoPro and shares supporting medical records. Successful Med Docs and/or Auth = Enter Backlog Direct Provider Process - Overview 16
Page 17
Myomo, Inc. Analyst Day - June 18th 2025 • Capture shape of arm and hand • Find and/or train therapist • Custom fabricate each MyoPro • Deliver and final fitting • Patient to therapy: 10-12 weeks • MyoCare for ~first year of use Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes Revenue Usually at Delivery Direct Provider Process - Overview 17
Page 18
Myomo, Inc. Analyst Day - June 18th 2025 Patients’ first conversation(s) and/or telehealth screening and/or clinical evaluation to determine initial candidacy for a MyoPro. PIPELINE REVENUE Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes BACKLOG Direct Provider Process - Overview Education via: • TV Ads • Social Media • Family/Friends • Physicians • Therapists • CPO’s • Capture shape of arm and hand • Find and/or train therapist • Custom fabricate each MyoPro • Deliver and final fitting • Patient to therapy: 10-12 weeks • MyoCare for ~first year of use Patient completes “face-to-face” with their Physician who orders the MyoPro and shares supporting medical records. 18
Page 19
Lead Generation Joe Chicoskie Director of Marketing 19
Page 20
Myomo, Inc. Analyst Day - June 18th 2025 • Joined Myomo in 2022 • Originally from Pittsburgh, PA, and lives in Dallas, TX • Marketing executive with corporate and advertising agency experience • Refined marketing efforts to maximize lead generation while minimizing cost per pipeline addition Joseph Chicoskie Director of Marketing 20 20
Page 21
Myomo, Inc. Analyst Day - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes Social Media TV Ads Referrals Social media is overall the most efficient and productive medium TV Ads educate the audience, generate leads, and lift results from digital ads. Organic Efforts Tradeshows - Orthotists/Prosthetists - Therapists (OT & PT) - PM&R Physicians - Case Managers - Local Events Industry Publications Word of mouth - thousands of users and trained therapists Lead Generation Efforts 21 21
Page 22
Myomo, Inc. Analyst Day - June 18th 2025 Facebook Creative Samples 22 22
Page 23
Myomo, Inc. Analyst Day - June 18th 2025 Facebook Creative Samples 23 23
Page 24
Myomo, Inc. Analyst Day - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes Cost/lead in April was equal to a year ago Advertising Spending 24
Page 25
Myomo, Inc. Analyst Day - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes If there is a saturation point for digital and TV advertising directly to stroke patients, we are not experiencing it at this time. Advertising Cost Per Lead 25
Page 26
Myomo, Inc. Analyst Day - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes Customer Acquisition Advertising Cost per Pipeline Add • Competition • Ad Strategy & Performance • Seasonality • Other factors (politics, etc) Cost/Lead • Operational Strategy & Performance • Lead type (payers, referrals, etc) • Cycle Times Lead Conversion Determinants of Cost Per Pipeline Add 26
Page 27
Myomo, Inc. Analyst Day - June 18th 2025 A complex patient journey that may take months, or years, to convert awareness into actions leading to an order. About half of each month’s pipeline adds come from leads generated during that month, and the rest come from older leads. Conversion of Leads to Pipeline Adds 27
Page 28
Myomo, Inc. Analyst Day - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes Leads increased 2.5-3X within a few months. New leads need time before entering the pipeline. For those patients that enter the Pipeline, many have an initial interaction with us and then pause the process. Later, the patients re-engage, complete the TH Screening, and enter the pipeline. Time is a Factor in Pipeline Adds 28 0% 5% 10% 15% 20% 25% 30% 35% <2 days 2-10 days 11-30 days 31-90 days 91-180 days 180-360 days 360+ days Time from Initial Lead to Pipeline Add
Page 29
Myomo, Inc. Analyst Day - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes Cost/Lead back to previous levels. Cost/Pipeline Add expected to be higher during rapid growth. 29 Marketing Efficiency Total $/Lead AD Spend/Pipeline Add Marketing Efficiency
Page 30
Field Operations Micah Mitchell Chief Commerical Officer 30
Page 31
Myomo, Inc. A nalyst D ay - June 18th 2025 Field Operations Field Operations Cu s t o m e r E xperience De p a rt m e n t (CXD) Patient Eligibility Team Regional MyoPro Orthotists (R MO’ s) Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes 31
Page 32
Myomo, Inc. A nalyst D ay - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes • 20 Intake Coordinators • Initial call with patient • Confirms paralyzed arm • Determines potential for funding • Schedules TH Screen with preference for “walk ins” • ~25,000 monthly inbound and outbound calls Intake 32
Page 33
Myomo, Inc. A nalyst D ay - June 18th 2025 Intake C oordinators call volume for incoming and outgoing calls is increasing month over month with additional room for expansion and is easily scalable • 13 Intake Coordinators – June 2024 • 20 Intake Coordinators – June 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes Intake is Easily Scalable 33
Page 34
Myomo, Inc. A nalyst D ay - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes • T eam consists of 5 Patient Eligibility Specialists + manager, who are all clinicians • T elehealth S creenings confirm clinical candidacy and initiate the process. • Patients can schedule an appointment or “walk in” immediately based on availability. • S uccessful T elehealth (T H ) S creenings result in a Pipeline A dd Patient View Clinician View Telehealth Screenings 34
Page 35
Myomo, Inc. A nalyst D ay - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes • S creening volume is increasing with additional capacity for growth • A pproximately 40% of screened patients move forward and are considered a pipeline add Telehealth Screenings 35
Page 36
Myomo, Inc. A nalyst D ay - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes • Patients must pass strict clinical inclusion/ exclusion criteria for pipeline add. A pprox. 60% are placed on hold • Some considerations are: T one/spasticity , range of motion, strength, E MG signal, mobility, comorbidities Screening Holds 36
Page 37
Myomo, Inc. A nalyst D ay - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes • E xample of a typical screening by a Patient Eligibility Specialist 37
Page 38
L uis C apestany Jack C oleman Janae H alter Ma t t Be a le Mel C arver Sam Mitchell S arah B ui Sean Allen K yle Sherk L ogan G oedde Chris Mullin David Hughes Matt Scoggin Myomo, Inc. A nalyst D ay - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes Olivia Sheffer – Field Operations Manager C ody D ean – Field Operations Manager Team of Highly Qualified CPO’s 38 38
Page 39
Myomo, Inc. A nalyst D ay - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes When a patient begins the fulfillment process, they exit the Pipeline and enter the B acklog FULFI LLM EN T: Shape Capture – In person or remote by licensed C PO – (Regional MyoPro Orthotist) Fabrication – tour later today Delivery/ Final Fitting – in clinic or patient’ s home by licensed C PO - (Regional MyoPro Orthotist) Fulfillment 39
Page 40
Myomo, Inc. A nalyst D ay - June 18th 2025 Lead Gen Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes 14 Regional MyoPro Orthotists territories We Will Come To You – Wherever You Are 40
Page 41
Medical Affairs Harry Kovelman, MD Chief Medical Officer 41
Page 42
Myomo, Inc. A nalyst D ay - June 18th 2025 H arry K ovelman, MD Chief Medical Officer •Live in Baltimore, MD •Over 25 years in leadership roles in medical device and pharmaceutical industry and lead communicating the Company’s scientific message to the payer community, clinicians, and patients. •Roles as Global Medical Director for Orthopedics at Ottobock Healthcare and Global Medical Affairs Director for Dynasplint Systems. Also held senior executive roles at Pacira Pharmaceuticals, and Helius Medical Technologies. •5+ years with Myomo 42 42
Page 43
Myomo, Inc. A nalyst D ay - June 18th 2025 L ead G en Int ake TH S creening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes C ollection of medical records and a physician’ s order proceed the F ulfillment process. 43
Page 44
Myomo, Inc. A nalyst D ay - June 18th 2025 Patient and Market Access Update L ead G en Intake TH Screening Med Docs & F unding Fulfillment & Field Ops Clinical Outcomes Successful Appeals! Part B Blues and Commercial MAOs United Healthcare 44 Medicare Part B
Page 45
Myomo, Inc. A nalyst D ay - June 18th 2025 Medical Affairs Department Patient Navigators- (15) with one Director and two leads • G uide patients through the Myomo journey • Obtain medical necessity documentation from providers Insurance Coordinators- 4 • S ubmit prior authorizations/appeals to insurance companies & obtain decision letters • V erify insurance, calculate Out-of-Pocket costs, and obtain S ingle C ase A greements Clinical Appeals Specialists- 3 • R eview documentation to ensure medical necessity is met prior to insurance submission • Write prior authorization requests and appeals Research-3 Director of R esearch, R esearch and Outcomes Manager, R esearch A ssociate L ead G en Intake TH Screening Med Docs & Funding Fulfillment & Field Ops Clinical Outcomes 45
Page 46
Myomo, Inc. A nalyst D ay - June 18th 2025 R evenue by Major Payer L ead G en Int ake TH S creening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 53% 47% Q1 2023 Med Advantage Other 18% 59% 23% Q1 2025 Med Advantage Medicare Other Payer Mix has changed dramatically Medicare coverage Med Advantage utilization management 46
Page 47
Myomo, Inc. A nalyst D ay - June 18th 2025 State of MA O A uthorization R ates Industry-wide MAO denial rates are in increasing, and MAO profitability is on the decline This has incentivized MAO plans to more tightly control utilization of healthcare services • The preauthorization and denial rates are high • In turn, causing providers to absorb additional costs to refile a claim and uncertainty about if they will be paid L ead G en Int ake TH S creening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 0% 5% 10% 15% 20% 25% 30% 35% 40% Q1'23 Q1'25 MAO Auth Rate 47
Page 48
Myomo, Inc. A nalyst D ay - June 18th 2025 Overcoming Payer Denials TOP THREE MOST COMMON REASONS Experimental / Investigational Not Covered by Original Medicare Not Medically Necessary AHA Guidelines Publication Review Review Definition of E/ I per Medicare Guidelines FDA Re gist r a t io n a n d De vice L isting Medicare Program Integrity Manual(13.5.4) including 7 foundational components Fa ce-to-F ace C hart Note documenting medical necessity D ocumented T herapy / Specialty Re co r d s Medicare F ee S chedule H C PC S Workgroup and C orrect C oding G uidelines Included in a D ME B enefit Ca t e go r y L ead G en Int ake TH S creening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 48
Page 49
Myomo, Inc. A nalyst D ay - June 18th 2025 Medicare Advantage Timeline to AL J and Decision….. a 5-10 month process! PA S ubmission 14-30 days 1st De n ia l 14-30 days 1st A ppeal S ubmitted 30-60 days 2nd Denial / Case F orwarded to Maximus Maximus Denial 30-60 days R equest A L J He a rin g 30-60 days He a rin g S cheduled 30-60 days AL J Decision L ead G en Int ake TH S creening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 49
Page 50
Myomo, Inc. A nalyst D ay - June 18th 2025 A dministrative L aw Judge (A L J) H earings D ocumentation C riteria for A L J H earing • Fa ce-to-F ace chart note documenting medical necessity for MyoPro • In-person E valuation with trial of demo device • When a denial is upheld by the Independent R eview E ntity (IR E ), Maximus, a case is eligible for AL J Hearing • A n A L J H earing is a telephonic hearing held by the Office of Medicare H earings and A ppeals • OMH A administers the nationwide A L J hearing program for beneficiaries under Medicare Parts A , B , C and D L ead G en Int ake TH S creening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 58% 42% ALJ Hearing Results YTD Win Loss 50
Page 51
Myomo, Inc. A nalyst D ay - June 18th 2025 MA O’ s have statutory , regulatory and contractual obligation under Medicare MA Os must cover everything that is reasonable and medically necessary for Medicare beneficiaries and must cover all services and devices covered by Original Medicare • Social Security Act. ﺑ1852; 42 U.S.C . ﺑ1395w-22; 42 C .F .R. ﺑ422.101(a) E xperimental or I nvestigational devices are ex cluded from Medicare coverage • 42 C .F .R. ﺑ411.15(o) Plans have flexibility to come up with a coverage policy in the absence of an L C D or NC D (42 C .F .R. ﺑ422.101(b)), but that does not undercut the obligation to cover all services covered by Original Medicare • H owever, we have found most of them are still applying their own C ommercial policies to restrict coverage! L ead G en Int ake TH S creening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 51 51
Page 52
Myomo, Inc. A nalyst D ay - June 18th 2025 Myomo A pproach / R oad to B roader R eimbursement Published F ee S chedule • C ontinue A ppeals • Increase Number of A L J H earings • E ven with legal fees, still provides a good contribution margin activity • Publish ME O R eview Paper and submit 1-year outcome follow -up manuscript • C ontinue R esearch efforts • E nter into Network C ontracts with more Payers P LAN E stablished codes (L 8701, L 8702) Medically Necessary as defined by Medicare Program Integrity Manual L ead G en Int ake TH S creening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 52
Page 53
Myomo, Inc. A nalyst D ay - June 18th 2025 In-Network Provider C ontracts- C ase by C ase Basis, E stablished Pricing, Faster Cycle Times and Approximately 27.2 Million L ives C overed; C an L ead to Policy C hange Payer Effective Date BCBS Plan 1 8/13/2024 BCBS Plan 2 11/21/2024 BCBS Plan 3 11/26/2024 Payer 1 5/1/2025 BCBS Plan 4 Signed Contract; Loading into system BCBS Plan 5 Signed Contract; Loading into system Payer Effective Date BCBS Plan 6 Signed Contract; Loading into system BCBS Plan 7 Received Contract; In Review Payer 3 Signed Contract; In Credentialing Payer 2 In Negotiations Payer 4 In Negotiations L ead G en Int ake TH Screening Me d Do cs & F unding Fulfillment & Field Ops Clinical Outcomes 53
Page 54
Clinical Outcomes Kathy Sawyers, PT, ATP Sr. Director – Clinical Outcomes 54
Page 55
Myomo, Inc. Analyst Day - June 18th 2025 Kathy Sawyers, PT, ATP Sr. Director - Clinical Outcomes • Physical Therapist with 30+ years of experience in patient care, clinical operations, and healthcare leadership • Primary focus is on enhancing clinical outcomes for Myomo clients • Manages internal and external clinical training and oversees MyoCare post- delivery care program • Collaborates cross functionally for program development, product management. • Works closely with the Business Development to expand the healthcare community’s clinical knowledge of Myomo products 55
Page 56
Myomo, Inc. Analyst Day - June 18th 2025 L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes Framing the Problem: Upper Extremity Paresis 800,000 patients are affected by stroke in the USA per year Results in 250,000 patients with Chronic Arm Weakness 56
Page 57
Myomo, Inc. Analyst Day - June 18th 2025 Myoelectric Technology The MyoPro combines existing myoelectric technology with neurorehabilitation principles and training techniques MyoPro Neuro Rehab Myoelectric Prosthetics Robotics L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 57
Page 58
Myomo, Inc. Analyst Day - June 18th 2025 L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 58
Page 59
Myomo, Inc. Analyst Day - June 18th 2025 MARK2 Mobile Arm Rehabilitation Kit L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 59
Page 60
Myomo, Inc. Analyst Day - June 18th 2025 MyoPro 2x Motion G MyoPro 2+ Motion W L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 60
Page 61
Myomo, Inc. Analyst Day - June 18th 2025 L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes Donning Objectives of the MyoPro 2x: Simplify the donning experience Promote greater independence for the user with donning Dorsal Hand Strap Thenar Hand Strap 61
Page 62
Myomo, Inc. Analyst Day - June 18th 2025 L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 62
Page 63
Myomo, Inc. Analyst Day - June 18th 2025 Therapy and Patient Trainers Support both Direct Billing and O&P Channels L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes Boots on the Ground All over the U.S. 63
Page 64
Myomo, Inc. Analyst Day - June 18th 2025 Over 1600 MyoPro Trained Therapists L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 64
Page 65
Myomo, Inc. Analyst Day - June 18th 2025 L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes Push Eat Reach Lift The P .E.R.L. Program - structured guidelines on how to incorporate the MyoPro into therapy Recommend a minimum of 10 -12 weeks of therapy Suggest 1:1 therapy sessions for 45 – 60 minutes 65
Page 66
Myomo, Inc. Analyst Day - June 18th 2025 Patient Selection and Evaluation Training MyoPro 2x Device Overview MyoPro 2x Fitting Guidelines Certification Test Certification Training L ead G en Int ake TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes 66
Page 67
Myomo, Inc. Analyst Day - June 18th 2025 L ead G en Intaken TH Screening Med D ocs & F unding Fulfillment & Field Ops Clinical Outcomes Meet Sandra 62 years old Stroke at age 37 Right arm weakness Minimal tone/spasticity 67
Page 68
Manufacturing Tour 68
Page 69
BREAK 69
Page 70
Manufacturing Colin Anderson Director of Global Operations 70
Page 71
Colin Anderson Director of Global Operations • Global Director of Operations at Myomo since 2023, overseeing manufacturing, supply chain, fulfillment, and engineering. • 15+ years of medical device industry experience, leading cross- functional teams in scaling operations, new product launches, and continuous improvement. • Proven leadership in operations and engineering at multiple MedTech companies, with a focus on streamlining production, reducing costs, and enabling rapid growth. • Educational background includes a B.E. and M.E. in Mechanical Engineering from Stevens Institute of Technology and an MBA from the University of Virginia Darden School of Business. 71 71
Page 72
Making a MyoPro Myomo, Inc. Analyst Day - June 18th 2025 72 72
Page 73
Manufacturing Process Map Shape Capture Model Generation First Station/ Subassemblies 3D Printing Supplier In-Process Inspection Final Assembly Kitting Final Inspection Shipping Motor Kit Assemblies User User Technical Customer Support Service & Repair Laptops Manuals Batteries/ Chargers Myomo, Inc. Analyst Day - June 18th 2025 73
Page 74
Shape Capture & Model Generation 1st Station & Subassemblies In-Process Inspection Final Assembly Kitting Final Inspection & Ship • Shape Capture Kits are ready to ship to customers for in person or remote shape capture. • Model Generation customizes the dimensions of each device to the user’s anatomy. Myomo, Inc. Analyst Day - June 18th 2025 74
Page 75
Shape Capture & Model Generation 1st Station & Subassemblies In-Process Inspection Final Assembly Kitting Final Inspection & Ship • Build custom subassemblies for each device based on user’s measurements • Supplier produces the custom orthotic shells Myomo, Inc. Analyst Day - June 18th 2025 75
Page 76
Shape Capture & Model Generation 1st Station & Subassemblies In-Process Inspection Final Assembly Kitting Final Inspection & Ship • Dimensionally verify all components at in-process inspection prior to assembly Myomo, Inc. Analyst Day - June 18th 2025 76
Page 77
Shape Capture & Model Generation 1st Station & Subassemblies In-Process Inspection Final Assembly Kitting Final Inspection & Ship • Several workstations set up for final assembly • Subcomponents are fastened together with rivets, screws, glue, pins, etc. • Cables are routed neatly through the device Myomo, Inc. Analyst Day - June 18th 2025 77
Page 78
Shape Capture & Model Generation 1st Station & Subassemblies In-Process Inspection Final Assembly Kitting Final Inspection & Ship •Devices are kitted with: •Spare batteries •Charger •Manuals •Laptop •Carrier Bag Myomo, Inc. Analyst Day - June 18th 2025 78
Page 79
Shape Capture & Model Generation 1st Station & Subassemblies In-Process Inspection Final Assembly Kitting Final Inspection & Ship • Devices are packaged after inspection and ready to ship • Several Final Inspection Stations • A kitted device arrives at the station and a full functional test is conducted to ensure the device is working properly Myomo, Inc. Analyst Day - June 18th 2025 79
Page 80
Manufacturing Update – The Past Year • Scaled capacity proportionately with demand • Moved to Burlington January 2025 • Capacity can be further increased with a 2 nd shift 80 80
Page 81
Phase I – Burlington • We outgrew our Boston HQ and moved to Burlington, MA. • New Facility was designed for better process flow and efficiency 81 81
Page 82
Phase II Expansion: Key Objectives Improvements • Add 18 cubicles • Add 3 offices • Add 1 conference room Office Expansion for New Hires • New flexible production space • Space for Insourcing • Increased stockroom capacity Production Capacity Increase • Engineering Model Shop • Reliability Lab Engineering Development Space Business Objectives Increased Capacity: Facilitate growth to 250 units/month Streamline Product and Process Flow Space for New Product Manufacturing Transfer Insourcing and Continuous Improvement Projects Mitigate Supply Chain Risk with Increased Safety Stock 82
Page 83
Phase II: On Track for July • Doubled First Floor Footprint • Enable insourcing of core subassemblies • Expanded Service area • Flex Production Space for New Products (MyoPro 3) • Expanded Engineering Model Shop and Reliability Lab • Increased Stockroom Capacity 83
Page 84
Cost Reduction and Risk Mitigation • Provide a Second Internal Source for: • FE & SP Joint – Q4 2025 Target – 15% Cost Reduction (estimate) • Grasp and Elbow Motor Assembly – Q1 2026 Target – 15% Cost Reduction (estimate) • Laptop Elimination: • Part of Companion App Project Launch • Majority of devices will ship without a laptop • Labor Optimization/Lean Manufacturing Implementation • Projects targeted on streamlining production & eliminating waste • Example: Automation of Liner Velcro cutting will take about 1 hour out of the manufacturing process Targeting 200 bps of gross margin improvement on a quarterly basis by the end of 2026 84
Page 85
International Operations John Frijters Managing Director Myomo Europe GmbH 85
Page 86
Myomo, Inc. A nalyst D ay - June 18th 2025 John Frijters Managing Director - Myomo Europe GmbH • Joined Myomo in 2020 • Currently residing in Göttingen, Germany • Previous executive roles in product management, sales and marketing and business development at ReWalk and Ottobock • Executive MBA from Kellog-WHU Global Program 86
Page 87
Myomo, Inc. A nalyst D ay - June 18th 2025 International Revenue – Germany & ROW Business Development Focus has been on Germany, other revenue in United Kingdom and Australia. 2022 2023 2024 R evenue $1.931.544 $3.284.176 $4.512.208 $1.500.000 $2.000.000 $2.500.000 $3.000.000 $3.500.000 $4.000.000 $4.500.000 $5.000.000 Revenue in USD 2022 2023 2024 Germany; 96% International - Other; 4% Revenue - 2024 Germany International - Other 87
Page 88
Myomo, Inc. A nalyst D ay - June 18th 2025 Reimbursement Environment in Germany • Approximately 82 million individuals in Germany possess health insurance. • Around 150,000 stroke survivors are recorded annually. • MyoPro has secured funding from over 50 insurance providers. • Funding eligibility for MyoPro has been validated by the Social Court. − S 20 KR 10171/21 SG Itzehoe (Mobil KK) − S 64 KR 40/22 SG Bremen (Barmer) − S 56 KR 1786/20 SG Berlin (DAK) & L 9 KR 210/21 LS Berlin-Brandenburg (DAK) − L 5 KR 126/23 LSG Rheinland-Pfalz (IKK Süd) Based on our track record, those who meet the qualifications for a MyoPro and adhere to the procedure throughout the entire process historically end up receiving a MyoPro. Statutory Health I nsurance ( G KV); 73 Mio; 89% Priv ate Health I nsurance ( P KV); 8,7 Mio; 11% T ype of Insurance by A pprox. Number of People - Germany Statutory Health Insurance (GK V ) Priv ate H ealth I nsurance (PK V ) 88
Page 89
Myomo, Inc. A nalyst D ay - June 18th 2025 MyoPro Patient Journey in Germany Step 1 - Patient Identification & Connect Step 2 - Clinical Evaluation & Screening Step 3 - Documentation & Justification Step 4 - Reimbursement & Approval Step 5 - Device Fabrication & Delivery Step 6 - Training, Use & Follow-Up Funding approval for a MyoPro frequently involves a 6 Month trial 89
Page 90
Myomo, Inc. A nalyst D ay - June 18th 2025 From Funding to Revenue - Germany 10% Funding to Direct Fitting • 10% Submission of request for funding results in direct approval for a MyoPro fitting • User receives MyoPro Device and ADL Training supported by Myomo in average after 220 days 65% of Funding Request are routed through a 6 month Trial • After review insurance wants more confirmation of user qualification and orders a trial in average 235 days after submitting the funding request • User receives MyoPro for a 6 month trail period during which progress has to be shown as evidence of compliance and eligibility 35% of Trials result in a Conversion • Positive outcome convinces the insurance and funding for a definitive fitting is approved • Conversion rate averages 35% after a trial 90
Page 91
Myomo, Inc. A nalyst D ay - June 18th 2025 MyoPro Revenue Distribution - Germany Direct Fitting 10% Trials − Trial duration approx 6 months − 35% conversion rate − Additional conversions after appeal/ SG appeal − Backed Up by Myomo Clinical Trainers MyoCare 35% Conversions − Most cases refitting using data collected during trial 70% of revenue relies on trials and successful completion of trials, resulting in a conversion to a definitive fitting with MyoPro Direct Fitting; 10% Tr i a l s; 65% Conversions; 35% Funding to Revenue 91 91
Page 92
Myomo, Inc. A nalyst D ay - June 18th 2025 Organizational Development Plan 2025 Enhance the team from 12 (12.2024) to 20 by end of 2025 − Cover open areas − Handle growing number of inquiries and trials − Grow trial conversation rate, defend market position − Build pipeline for 2026 Scaling Team CTM − Manages the user connection − Trains the therapist − Provides MyoCare support during Trial and Delivery − Influences the conversion rate Expansion of our team will increase our ability to see more customers and deliver more MyoPro devices 2 6 4 12 2 11 7 20 0 5 10 15 20 25 GmbH CTM BDM TE AM T eam M yomo GmbH 2024 92
Page 93
Myomo, Inc. A nalyst D ay - June 18th 2025 Development & Growth Initiatives Scaling the GmbH Operation Larger team Smaller areas Higher frequency of visits Less travel time More contact & contacts .... Grow Referring Medical Specialist Network Visits to OT/PT therapist, doctor, clinic, CPO Fairs / Congress / Symposia MyoPro can be prescribed! Increase Coverage & Awareness Social Media Print Online Marketing SEO / SEA Exhibitions and Fairs Smart and Digital Processes Online Pre-Screening Integrate MS Dynamics 365 Rx through Myomo Leverage MyoCare 93
Page 94
Myomo, Inc. A nalyst D ay - June 18th 2025 94 Long Term Revenue Revenue is projected to grow to $15 million by 2028, reflecting strong market momentum and strategic execution. $1.000.000 $3.000.000 $5.000.000 $7.000.000 $9.000.000 $11.000.000 $13.000.000 $15.000.000 2022 2023 2024 2028 B usiness G rowth 35% CAGR 52% CAGR 94
Page 95
O&P Channel Micah Mitchell Chief Commercial Officer 95
Page 96
Myomo, Inc. Analyst Day - June 18th 2025 SCOPE • Licensed clinicians assess, design, fabricate, fit, and monitor • Serves patients with musculoskeletal, neurological, and amputation-related conditions • Insurance in-network contracts generally in place MARKET TRENDS • Focus on patient outcomes and clinical data • Some consolidation and PE involvement INDUSTRY CHALLENGES • Heavy administrative & documentation burden • Reimbursement cuts and prior auth delays & denials • Clinician recruitment and retention issues PROVIDER SIZE • A few national providers • Regional Providers with 3-20 locations • Local Family Owned Providers • Hospital/Clinic Based O&P Channel Primer 96
Page 97
Myomo, Inc. Analyst Day - June 18th 2025 “We are looking to expand some of our technology offerings, both in prosthetics and orthotics. And obviously, the MyoPro fits right into that initiative.” Aaron Sorensen Owner /LCPO Restorative Health Services Group in Murfreesboro, TN 97
Page 98
Myomo, Inc. Analyst Day - June 18th 2025 O&P Channel launch, post MyoPro2x with full MyoPro certification to allow COE’s to order without our involvement, is going well, with signs of growth. Can we get commitment from O&P leaders and clinicians? Can we successfully train CPO’s on clinical aspects? Can we train COE’s to properly handle funding protocols? Will COE’s take the financial risk, even with a prior auth or appropriate Medicare documentation? Will COE’s properly handle marketing/salesmanship so that all stroke patients are exposed to the MyoPro early in their post-stroke journey? O&P Channel Updates 98
Page 99
Myomo, Inc. Analyst Day - June 18th 2025 99 • Learn about MyoPro • Agree to Pricing, Terms & Conditions • Agree to Clinical Protocols COE Commits • On Demand • Then COE builds pipeline – at least 3 patients • Schedules In- Services for Eval Day Initial Eval Training • 8-12 Hours • 3+ MARK evals • In-Services • COE builds Pipeline • COE gets Auths for Fitting Days Eval Day Certification Step 1 • ~8 Hours • Fitting Training via “shared fitting” • In-Services too Fitting Day 1 • 2nd patient - CPO with assistance • 3rd patient - CPO drives process • CPO pass Exam Fitting Day 2 & 3 • COE orders independentl • CPO handles clinical care - delivery and post-delivery • CPO handles most repairs CERTIFIED COE O&P Channel – Eval Training and Certification Process 99
Page 100
Myomo, Inc. Analyst Day - June 18th 2025 “I’ve been excited about this since 2013 when I was first exposed to the MyoPro. And now with Medicare having a code for this, this is going to be able to provide really life changing orthotic care for patients that we really have not been able to do in the past.” Jason Auyer Owner / LCPO Alliance Prosthetics & Orthotics in Gainesville, GA 100
Page 101
Myomo, Inc. Analyst Day - June 18th 2025 Infrastructure and leaders now in place Rapid growth expected for next few years O&P Channel Updates 101
Page 102
Myomo, Inc. Analyst Day - June 18th 2025 O&P Channel Updates 2028 Projection Range 102
Page 103
Myomo, Inc. Analyst Day - June 18th 2025 “Our goal is to get 20 referrals over the next three to four months that turn into five to seven [MyoPro] patients.” Roger Mermelstein US Operations Eqwal Group in Washington D.C. 103
Page 104
Product Development Malcolm Bock V.P. Engineering and Product Strategy 104
Page 105
Myomo, Inc. Analyst Day - June 18th 2025 Malcolm Bock VP Engineering & Product Strategy • Joined Myomo in 2023 • 30+ years experience in electro-mechanical medical device product development across both small/start-up, medium, and large companies, including Respiratory Motion, Bionik Labs and Covidien/Medtronic • Spans products including Diagnostic, Monitoring, Therapeutic, General Medical • Specialize in building strong cross functional product development teams focused on launching state of the art, innovative products • Track record of innovation: 52 Patents (33 issued, 19 pending) 105
Page 106
Myomo, Inc. Analyst Day - June 18th 2025 Product Roadmap 106
Page 107
Myomo, Inc. Analyst Day - June 18th 2025 MARK 2 (Launched January 2025) Mobile Arm Rehabilitation Kit : Used by Clinicians to evaluate suitability of MyoPro for each unique candidate/user: New version of the device incorporated the following improvements: • 3D printed shells • ‘One Size Fits All’ design featuring built in adjustability (Forearm Bar, Humeral Shell Length, Sized Pads, Hand Shells, and Finger Saddles • More user-friendly adjustability for changing sizes • Now manufactured in our Burlington facility vs. outsource manufacturer 107
Page 108
Myomo, Inc. Analyst Day - June 18th 2025 MyoPro 2x (Launched April 2025) MyoPro 2x is a redesign of the mechanical orthotic elements to minimize donning time and improve sensor contact. The following key improvements were integrated into MyoPro 2x: • Improved Hand Strap, Shell, & Motor Closure • Improved Forearm and Humeral Shell design for ease of donning • Better more reliable sensor suspension system • Incorporate Poke Yoke easy step by step application methodology to reduce training time 108
Page 109
Myomo, Inc. Analyst Day - June 18th 2025 MyoPro 2x Training Video (80 sec.) 109
Page 110
Myomo, Inc. Analyst Day - June 18th 2025 MyoPro Companion App (2x & Mark 2) to Serve as the Key Communication Platform for the Future • Reduced COGS - leveraging patient’s existing mobile device as opposed to supplying a new laptop with each device delivery • Improved reliability due to decreased reliance on third-party materials such as laptops and laptop chargers and Zoom laptop app • Ease of use due to easier accessibility to an app vs a laptop and improved patient screens • Reliable and consistent data access with new cloud infrastructure • Platform for future feature launches to support device adoption and functional outcomes 110
Page 111
Myomo, Inc. Analyst Day - June 18th 2025 Competition (Germany): Slimmer, but more limited addressable market Competitor Advantage: Smaller more modern look • Smaller motor and slightly smaller battery reduce the device footprint • Adjustable buckles add a modern look and easy to use • Simplified hand donning—finger piece can be donned independently MyoPro Advantage: More powerful and customizable for broader market reach and greater functionality • Higher-torque motor enables support for patients with higher tone or larger builds and tasks involving lifting objects • Individually configurable sensors allow tailored support for rehab, device training, and complex tone profiles • EMG signal visualization supports users during training and use • UI on device for ease-of-use and customization • Wrist rotation lock ensures consistent positioning for functional activities Vincent Systems Neo1 111
Page 112
Myomo, Inc. Analyst Day - June 18th 2025 MyoPro3: Maximizing Patient Functional Outcomes • Goal is to restore “the functions of the patient’s weak limbs.” • Further enhanced functionality will be measured against: –Validated outcome measures (objective measurements of functionality) –Patient reported outcomes (subjective patient reports) MyoPro3 expected to be designed to perform well for both objective and subjective evaluation methods 112
Page 113
Myomo, Inc. Analyst Day - June 18th 2025 MyoPro3 Expected to Leverage the Latest Technological Advancements to Enhance Patient Function • Donnability: Intuitive design with more comfortable cuff materials and improved closure system • Reliability: Increased patient utilization and satisfaction with reliable, consistent, predictable, and smoother device movements through better sensing and motion control. • Functional Activities: Improved grasp design, will be optimized for meaningful patient activities and support validated outcome studies • Competitive edge: Data access enables advanced tools to optimize device movement, patient adoption, and clinical support. Modular solution allows for family of products to follow 113
Page 114
Myomo, Inc. Analyst Day - June 18th 2025 MyoPro 3 Key Technologies Orthosis/Bracing EMG Sensing Robotic Grasp Electronics Pack Robotic Elbow Orthosis/Structure Shoulder Harness 114
Page 115
Myomo, Inc. Analyst Day - June 18th 2025 MyoPro 3 Expected to Provide 115 Design to the subjective and objective tests for strongest payer reimbursement positioning and enabling meaningful user function. Modular platform technology to support future new product releases and enhancements Proactive monitoring and state-of-the- art core technology base Leverage the latest technology in brace design and AI to enable real-time device customization.
Page 116
Finance David Henry CFO 116
Page 117
Myomo, Inc. A nalyst D ay - June 18th 2025 David Henry Chief Financial Officer • CFO at Myomo since 2019. • Prior to Myomo, I was CFO at EOS Energy Storage (pre-SPAC), American Superconductor Corp and AMI Semiconductor Corp. Nearly 20 years as public-Company CFO • Broad background in Finance and Accounting, including Controller, Financial Analysis and Internal Audit • BSBA from UC Berkeley; MBA from Santa Clara University 117
Page 118
Myomo, Inc. A nalyst D ay - June 18th 2025 Financial Snapshot $- $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 $14.0 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Revenue 50.0% 55.0% 60.0% 65.0% 70.0% 75.0% 80.0% Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Gross Margin $- $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Operating E xpenses 100 150 200 250 300 350 0 100 200 300 400 500 600 700 800 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Pipeline A dds and B acklog Pipeline Adds Backlog 118
Page 119
Myomo, Inc. A nalyst D ay - June 18th 2025 Components of Spending 52% 16% 7% 6% 5% 3% 2%2% 9% Payroll & Benefits Advertising Consultants Travel Outside Services Legal Rent (opex portion) Depreciation All Other Q1 2025 Operating Expenses 68% of Q1 2025 operating expenses were payroll and advertising 0% 20% 40% 60% 80% 100% 120% Other Overhead Warranty Rent Payroll + Benefits Material Q1 2025 COGS 26% of COGS is Material - 74% Labor and Overhead 119
Page 120
Myomo, Inc. A nalyst D ay - June 18th 2025 As previously disclosed, negative Operating Cash Flow in Q2 is expected to be greater than Q1 due to: • Payment of 2024 incentive compensation • Higher expected Q2 operating loss $(4.0) $(3.0) $(2.0) $(1.0) $- $1.0 $2.0 $3.0 $4.0 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Operating C ash F low Cash Position • $4M line of credit - $1.9M available • $3M term loan facility • Both facilities undrawn 120
Page 121
Myomo, Inc. A nalyst D ay - June 18th 2025 Long Term Model - $100M in Revenue by 2028 0 20 40 60 80 100 120 Revenue $M Revenue C A GR = 32% 2016 2017 2018 2019 2020 2021 2022 2023 2024 2028 Other LT targets: • Gross Margin: 70 – 72% • EBITDA Margin: 15% - 20% • Cash Flow Breakeven Revenue: $17M-$18M per quarter 121
Page 122
Myomo, Inc. A nalyst D ay - June 18th 2025 Model Revenue by Channel 79% 5% 3% 13% Q1'25 R evenue by C hannel Direct Billing US O&P VA International 62% 20% 3% 15% Direct Billing US O&P VA International Model Revenue by Channel at $100M 122
Page 123
Myomo, Inc. A nalyst D ay - June 18th 2025 How Do We Achieve the LT Targets? • Continue direct billing efforts. Approximately 25% annual revenue growth, assuming modest improvement in some conversion rates. • U.S. O&P channel is a large growth driver. Based on earlier sensitivity analysis –we believe our model O&P revenue is in the “middle of the fairway” in terms of the opportunity. • Continue growing international revenue. Can achieve the target on a lower growth rate vs. historical. Current competition in Germany appears to be limited. • Modest manufacturing cost reductions assumed, including the Companion App and volume pricing on materials. Fixed overhead absorption benefit since no additional space required to deliver this plan. • Modest R&D growth assumed. 2025 will be a year of investment in R&D, after which we believe it can sustain our existing products and deliver on the product roadmap • Spend the advertising necessary to make sure the top of the funnel is full. 123
Page 124
Myomo, Inc. A nalyst D ay - June 18th 2025 Takeaways • Our target is to achieve $100 million in annual revenue by 2028. • O&P channel targeted to be 20% revenue by 2028. • Revenue level for operating cash flow breakeven is ~$17M - $18M per quarter. • We’ll spend the advertising dollars necessary to ensure continued growth in the direct billing channel. Would re-assess based on a material increase in cost/lead. • Plan to moderate growth in R&D over the plan horizon. 124
Page 125
Closing Remarks Paul Gudonis CEO 125